AN2 Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
AN2 Therapeutics (Nasdaq: ANTX), a biopharmaceutical company specializing in boron chemistry-based small molecule therapeutics, has announced its participation in the upcoming Oppenheimer 35th Annual Healthcare Life Sciences Conference.
Eric Easom, who serves as Co-Founder, Chairman, President and CEO, will deliver a corporate overview at the virtual event on Wednesday, February 12, 2025, at 3:20 PM ET. Interested parties can access the presentation through a webcast available on the Investors section of AN2 Therapeutics' website. The presentation recording will remain accessible for a minimum of 30 days after the event.
AN2 Therapeutics (Nasdaq: ANTX), una compagnia biofarmaceutica specializzata in therapeutics a piccole molecole basati sulla chimica del boro, ha annunciato la sua partecipazione al 35° Convegno Annuale sulle Scienze della Vita di Oppenheimer.
Eric Easom, cofondatore, presidente e CEO, presenterà una panoramica aziendale durante l'evento virtuale che si terrà mercoledì 12 febbraio 2025, alle 15:20 ET. Le parti interessate possono accedere alla presentazione tramite un webcast disponibile nella sezione Investitori del sito di AN2 Therapeutics. La registrazione della presentazione rimarrà accessibile per un minimo di 30 giorni dopo l'evento.
AN2 Therapeutics (Nasdaq: ANTX), una compañía biofarmacéutica especializada en terapéuticas de pequeñas moléculas basadas en química de boro, ha anunciado su participación en la 35ª Conferencia Anual de Ciencias de la Vida de Oppenheimer.
Eric Easom, cofundador, presidente y CEO, ofrecerá una visión general de la empresa en el evento virtual el miércoles 12 de febrero de 2025, a las 15:20 ET. Las partes interesadas pueden acceder a la presentación a través de una transmisión web disponible en la sección de Inversores del sitio web de AN2 Therapeutics. La grabación de la presentación permanecerá accesible por un mínimo de 30 días después del evento.
AN2 Therapeutics (Nasdaq: ANTX), 붕소 화학 기반 소분자 치료제를 전문으로 하는 바이오제약 회사는 오펜하이머 제35회 연례 헬스케어 생명과학 컨퍼런스에 참여한다고 발표했습니다.
공동 창립자이자 회장, CEO인 Eric Easom은 2025년 2월 12일 수요일 오후 3:20 ET에 열리는 가상 행사에서 회사 개요를 발표할 것입니다. 관심 있는 사람들은 AN2 Therapeutics 웹사이트의 투자자 섹션에서 제공되는 웹캐스트를 통해 발표를 확인할 수 있습니다. 발표 녹화는 행사 후 최소 30일 동안 접근할 수 있습니다.
AN2 Therapeutics (Nasdaq: ANTX), une entreprise biopharmaceutique spécialisée dans les thérapeutiques à petites molécules basées sur la chimie du bore, a annoncé sa participation à la 35e Conférence Annuelle sur les Sciences de la Vie d'Oppenheimer.
Eric Easom, cofondateur, président et CEO, fera une présentation de l'entreprise lors de l'événement virtuel qui se tiendra mercredi 12 février 2025, à 15h20 ET. Les parties intéressées peuvent accéder à la présentation via un webcast disponible dans la section Investisseurs du site web d'AN2 Therapeutics. L'enregistrement de la présentation restera accessible pendant un minimum de 30 jours après l'événement.
AN2 Therapeutics (Nasdaq: ANTX), ein biopharmazeutisches Unternehmen, das sich auf auf Borchemie basierende kleine Moleküle als Therapeutika spezialisiert hat, hat seine Teilnahme an der 35. jährlichen Gesundheits- und Lebenswissenschafts-Konferenz von Oppenheimer bekannt gegeben.
Eric Easom, Mitgründer, Vorsitzender, Präsident und CEO, wird bei der virtuellen Veranstaltung am Mittwoch, den 12. Februar 2025, um 15:20 Uhr ET eine Unternehmensübersicht geben. Interessierte können die Präsentation über ein Webcast auf der Investoren-Seite der Website von AN2 Therapeutics abrufen. Die Aufzeichnung der Präsentation bleibt mindestens 30 Tage nach der Veranstaltung zugänglich.
- None.
- None.
Details of the event are as follows:
Oppenheimer 35th Annual Healthcare Life Sciences Conference (virtual)
- Eric Easom, Co-Founder, Chairman, President and CEO will provide a corporate overview on Wednesday, February 12, 2025 at 3:20pm ET.
A webcast of the presentation can be accessed on the Investors section of the AN2 Therapeutics website at www.an2therapeutics.com. An archived replay will be available for at least 30 days following the presentation.
About AN2 Therapeutics, Inc.
AN2 Therapeutics, Inc. is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. AN2 has a pipeline of boron-based compounds in development for Chagas disease, NTM, and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology. For more information, please visit our website at www.an2therapeutics.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250129335824/en/
COMPANY CONTACT:
Lucy O. Day
Chief Financial Officer
l.day@an2therapeutics.com
INVESTOR AND MEDIA CONTACT:
Anne Bowdidge
ir@an2therapeutics.com
Source: AN2 Therapeutics, Inc.
FAQ
When is AN2 Therapeutics (ANTX) presenting at the Oppenheimer Healthcare Conference 2025?
How can investors watch AN2 Therapeutics' (ANTX) Oppenheimer conference presentation?
How long will AN2 Therapeutics' (ANTX) Oppenheimer conference presentation be available for replay?
What is AN2 Therapeutics' (ANTX) main focus in drug development?
Is the Oppenheimer Healthcare Conference 2025 featuring AN2 Therapeutics (ANTX) in-person or virtual?
